Table 2.
Patient-Level (Worse Eye) 8th Edition AJCC cT Category of Anatomic Extent in 1841 Patients with Retinoblastoma by Treatment Modality
| AJCC Clinical Tumor Category | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|||||||||
| cT2a | cT2b | cT3a | cT3b | cT3c | cT3d | cT3e | Total | |||
| Treatment modality | Primary enucleation | Count | 110 | 410 | 13 | 123 | 284 | 161 | 27 | 1128 |
| % treatment modality | 9.8 | 36.3 | 1.2 | 10.9 | 25.2 | 14.3 | 2.4 | 100.0 | ||
| % AJCC subcategory | 56.1 | 50.4 | 59.1 | 74.1 | 73.0 | 79.3 | 52.9 | 61.3 | ||
| % total | 6.0 | 22.3 | 0.7 | 6.7 | 15.4 | 8.7 | 1.5 | 61.3 | ||
| Systemic chemotherapy followed by secondary enucleation | Count | 32 | 164 | 5 | 19 | 61 | 23 | 11 | 315 | |
| % treatment modality | 10.2 | 52.1 | 1.6 | 6.0 | 19.4 | 7.3 | 3.5 | 100.0 | ||
| % AJCC subcategory | 16.3 | 20.1 | 22.7 | 11.4 | 15.7 | 11.3 | 21.6 | 17.1 | ||
| % total | 1.7 | 8.9 | 0.3 | 1.0 | 3.3 | 1.2 | 0.6 | 17.1 | ||
| Systemic chemotherapy and eye salvage | Count | 54 | 240 | 4 | 24 | 44 | 19 | 13 | 398 | |
| % treatment modality | 13.6 | 60.3 | 1.0 | 6.0 | 11.1 | 4.8 | 3.3 | 100.0 | ||
| % AJCC subcategory | 27.6 | 29.5 | 18.2 | 14.5 | 11.3 | 9.4 | 25.5 | 21.6 | ||
| % total | 2.9 | 13.0 | 0.2 | 1.3 | 2.4 | 1.0 | 0.7 | 21.6 | ||
| Total | Count | 196 | 814 | 22 | 166 | 389 | 203 | 51 | 1841 | |
| % total | 10.6 | 44.2 | 1.2 | 9.0 | 21.1 | 11.0 | 2.8 | 100.0 | ||
| Patient-Level (Worse Eye) AJCC-OOTF Size Group in 1416 Patients with Retinoblastoma by Treatment Modality | |||||||
|---|---|---|---|---|---|---|---|
|
| |||||||
| AJCC-OOTF Size Group |
|||||||
| 1: < 50% Globe Involved | 2: > 50% and < 2/3 Globe Involved | 3: > 2/3 of Globe Involved | 4: Diffuse Infiltrating Retinoblastoma | Total | |||
| Treatment modality | Primary enucleation | Count | 141 | 175 | 507 | 107 | 930 |
| % treatment modality | 15.2 | 18.8 | 54.5 | 11.5 | 100.0 | ||
| % AJCC-OOTF Size Group | 48.8 | 54.9 | 75.0 | 81.1 | 65.7 | ||
| % total | 10.0 | 12.4 | 35.8 | 7.6 | 65.7 | ||
| Systemic chemotherapy followed by secondary enucleation | Count | 57 | 55 | 96 | 8 | 216 | |
| % treatment modality | 26.4 | 25.5 | 44.4 | 3.7 | 100.0 | ||
| % AJCC-OOTF Size Group | 19.7 | 17.2 | 14.2 | 6.1 | 15.3 | ||
| % total | 4.0 | 3.9 | 6.8 | 0.6 | 15.3 | ||
| Systemic chemotherapy and eye salvage | Count | 91 | 89 | 73 | 17 | 270 | |
| % treatment modality | 33.7 | 33.0 | 27.0 | 6.3 | 100.0 | ||
| % AJCC-OOTF Size Group | 31.5 | 27.9 | 10.8 | 12.9 | 19.1 | ||
| % total | 6.4 | 6.3 | 5.2 | 1.2 | 19.1 | ||
| Total | Count | 289 | 319 | 676 | 132 | 1416 | |
| % total | 20.4 | 22.5 | 47.7 | 9.3 | 100.0 | ||
AJCC = American Joint Committee on Cancer; c = clinical; OOTF = Ophthalmic Oncology Task Force; T = tumor.